MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/200/0.1/19.09.25 | Delayed Börse Stuttgart 02:12:02 2024-07-17 am EDT | ||
| 0.61 EUR | -3.17% |
|
| Current month | -16.00% | ||
| 1 month | -16.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 0.61 | -3.17% |
| 24-07-16 | 0.63 | -1.56% |
| 24-07-15 | 0.64 | -5.88% |
| 24-07-12 | 0.68 | +9.68% |
| 24-07-11 | 0.62 | -10.14% |
Delayed Quote Börse Stuttgart
Last update July 17, 2024 at 02:12 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME8N08 |
| ISIN | DE000ME8N080 |
| Date issued | 2024-02-13 |
| Strike | 200 $ |
| Maturity | 2025-09-19 (430 Days) |
| Parity | 10 : 1 |
| Emission price | 0.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.89 € |
|---|---|
| Lowest since issue | 0.38 € |
| Spread | 0.15 € |
| Spread % | 23.44% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
956.8
DKK
Spread / Average Target
-1.36%
- Stock Market
- Warrants
- Warrant
